More Company News

ANGLE

Update on submission for FDA clearance
04 Jun 2021Read More

ANGLE

Potential to prevent breast cancer relapse
01 Jun 2021Read More

ANGLE

Parsortix demonstrates oesophageal cancer utility
20 May 2021Read More

ANGLE

Parsortix study uncovers targets in TNBC patients
11 May 2021Read More

ANGLE

FY20 preliminary results
29 Apr 2021Read More

ANGLE

Completion of enrolment in ovarian cancer study
26 Apr 2021Read More

ANGLE

First large-scale pharma services contract secured
16 Apr 2021Read More

ANGLE

Global launch of clinical services laboratories
30 Mar 2021Read More

ANGLE

Update on submission for FDA clearance
04 Mar 2021Read More

Return to ANGLE
© 2019-21 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).